PCI High Potent Manufacturing
LB Bohle – 10.06.2025
Temax_Krautz

Current Edition

Current Edition

Subsection - CDMO

Examining how innovative technologies, integrated manufacturing approaches and AI are shaping manufacturing.

Continue reading

Subsection - Injectables

Exploring advances in injectable drug delivery and sterile manufacturing, designed to improve patient-centric delivery.

Continue reading

Subsection - Neurodegenerative Diseases

Exploring emerging approaches to neurodegenerative disease research and treatment.

Continue reading

Subsection - Nasal & Pulmonary

Highlighting how advances in nasal and pulmonary drug delivery, formulation, devices and analytics are enabling more complex therapies.

Continue reading

Advertisement

CPHI 2027
DDL 2026

Advertisement

Nipro August 26

Advertisement

Merxin March 2026

Advertisement

Aurisco 300×250

Advertisement

Lifecore Biomedical

Valneva reveals chikungunya vaccine data

VLA1553 had a high seroresponse rate among participants 28 days after receiving a single administration.

Valneva – a company focused on developing vaccines for global conditions – has announced that critical phase 3 data in relation to its single-shot chikungunya vaccine, VLA1553, has been published in The Lancet.

The candidate is a single-shot live-attenuated vaccine and has been subjected to a double-blind, multi-location, placebo-controlled, randomised phase 3 trial. Consequently, the results demonstrated that VLA1553 had a very high seroresponse rate of 98.9% among participants, 28 days after receiving a single administration.

The immunogenicity profile, therefore, was similar across younger and older adult populations, while 96% of participants maintained seroresponse six months after their vaccination.

Furthermore, VLA1553 was generally safe and equally well tolerated in both younger and older adults.

Juan Carlos Jaramillo, chief medical officer of Valneva, was very optimistic about the vaccine candidate and the impact it could make: “This publication in The Lancet underlines the strength of VLA1553’s scientific approach and is consistent with the quality of our pivotal phase 3 study.”

He added: “We are pleased that more detailed results on our single-shot chikungunya vaccine candidate are now available to the scientific and broader public health communities.”

VLA1553 remains the only global chikungunya vaccine candidate undergoing regulatory review processes. Meanwhile, a biologic license application is currently under ‘priority review’ by the US Food and Drug Administration.

If approval is granted, VLA1553 could then become the very first licensed and available chikungunya vaccine.

Chikungunya is a viral disease caused by the chikungunya virus and transmitted by Aedes mosquitoes. Four to seven days after a bite, infection leads to symptomatic disease in 72 to 92% of impacted people.

Advertisement

MedPharm 16/07

Advertisement

Biopharma group march 2026

Advertisement

Silgan March 2026

Advertisement

Terumo 06/26

Advertisement

Scott Pharma – 25.03.2025

Advertisement

Bespak

Advertisement

Solstice

Advertisement

Bachem skyscraper
Tjoapack
Aptar – 08/01/2026